Browsing Tag
OcuMension Therapeutics
2 posts
Glaucoma drug NCX 470 reaches another major market as Nicox’s partner strategy pays off
NCX 470 enters China review as Nicox targets glaucoma royalties across China, the U.S. and Japan. See what the filing means for growth.
August 12, 2026
OcuMension secures Alcon eye drop rights with 16.7% stake, marking major strategic shift
OcuMension Therapeutics has struck a landmark deal with Alcon Inc., acquiring commercialization rights for a portfolio of eye…
August 13, 2024